On March 29, 2016, the United States Food and Drug Administration (FDA) updated its so-called Paragraph IV Certification List with two (2) new drugs for which the FDA has received abbreviated new drug applications (ANDAs) containing a patent challenge. The targeted new drug products are: (i) ApoPharma Inc.’s Ferriprox (Deferiprone) Tablets, 500mg; and (ii) Oak Pharmaceuticals, Inc.'s (a subsidiary of Akorn Pharmaceuticals) Zioptan (Tafluprost) Ophthalmic Solution, 0.0015%. The dates of submission of the respective ANDAs containing a patent challenge for these two new drug products are January 29, 2016 and February 10, 2016.